Neuromyelitis Optica Spectrum Disorders clinical trials at University of California Health
2 in progress, 0 open to eligible people
Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Sorry, in progress, not accepting new patients
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
at UCSF
Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Sorry, not currently recruiting here
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).
at UCSD
Our lead scientists for Neuromyelitis Optica Spectrum Disorders research studies include Emmanuelle Waubant Jennifer Sharon Graves, MD, PhD.
Last updated: